# Phase 4 asthma trials recruiting: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 4 for asthma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 asthma trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/asthma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07858773 | Prevent Wheeze Trial | Norwegian University of Science and Technology | Phase 4 | Not yet recruiting | Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858773) |
| June 24, 2026 | NCT07666490 | BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI \[BDP/FF/GB - 100/6/12.5 μg\]) vs Single Inhaler ICS/LABA... | Chiesi Farmaceutici S.p.A. | Phase 4 | Recruiting | Asthma | 644 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07666490) |
| June 24, 2026 | NCT07664527 | Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | University of Wisconsin, Madison | Phase 4 | Not yet recruiting | Asthma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664527) |
| June 16, 2026 | NCT07651891 | Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice | Karolinska Institutet | Phase 4 | Recruiting | Allergic Rhinitis, Asthma (Diagnosis) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651891) |
| February 23, 2026 | NCT07426458 | Ventilation and Perfusion in Asthmatics | University of Miami | Phase 4 | Recruiting | Asthma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07426458) |
| November 21, 2025 | NCT07241117 | CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma | Washington University School of Medicine | Phase 4 | Recruiting | Moderate to Severe Asthma | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241117) |
| November 13, 2025 | NCT07228052 | Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department | Montefiore Medical Center | Phase 4 | Recruiting | Asthma | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228052) |
| September 11, 2025 | NCT07166939 | 45th Multicenter Airway Research Collaboration | Massachusetts General Hospital | Phase 4 | Recruiting | Asthma Acute, Asthma Exacerbation, Asthma, Asthma Control Level | 1,860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166939) |
| July 8, 2025 | NCT07052942 | Individualizing Treatment for Asthma in Primary Care (Full Study) | DARTNet Institute | Phase 4 | Recruiting | Asthma, Asthma Attack, Asthma Exacerbations | 3,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052942) |
| May 14, 2025 | NCT06970080 | Therapeutic Relevance of Abnormal Airway Morphology in Asthma | McMaster University | Phase 4 | Recruiting | Asthma | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970080) |
| February 10, 2025 | NCT06818019 | Withdrawal of Dupilumab in Severe Asthma | University Hospital, Toulouse | Phase 4 | Recruiting | Severe Asthma | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06818019) |
| November 26, 2024 | NCT06705764 | Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | University of Alberta | Phase 4 | Recruiting | Severe Asthma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06705764) |
| November 7, 2024 | NCT06679465 | Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response | University of Saskatchewan | Phase 4 | Not yet recruiting | Asthma Bronchiale | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679465) |
| August 23, 2024 | NCT06568445 | Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | Not yet recruiting | Bronchial Asthma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06568445) |
| April 26, 2024 | NCT06385236 | Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | University of California, San Diego | Phase 4 | Recruiting | Moderate to Severe Asthma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06385236) |
| September 7, 2023 | NCT06027073 | Biologics and Sublingual Immunotherapy | Medical University of Silesia | Phase 4 | Not yet recruiting | Asthma, Allergic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06027073) |
| February 21, 2021 | NCT04763447 | Short Treatment with Omalizumab for Severe Asthma | Assistance Publique - Hôpitaux de Paris | Phase 4 | Recruiting | Asthma | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04763447) |
| February 8, 2021 | NCT04743791 | Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma | Sponsor not shown (see the record) | Phase 4 | Recruiting | Asthma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04743791) |
| May 8, 2020 | NCT04380038 | Viral Infection in Asthma (VIA) Study | University of Virginia | Phase 4 | Recruiting | Asthma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04380038) |
| March 26, 2019 | NCT03889743 | Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing | St. Olavs Hospital | Phase 4 | Recruiting | Asthma, Inflammation | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03889743) |
| October 21, 2010 | NCT01225913 | Mechanism(s) of Airflow Limitation During Exacerbation of Asthma | Sponsor not shown (see the record) | Phase 4 | Recruiting | Asthma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01225913) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| University of California, San Diego | 1 |
| [Chiesi Farmaceutici S.p.A.](https://specstream.ai/data/clinical-trials/company/chiesi-farmaceutici-s-p-a) | 1 |
| DARTNet Institute | 1 |
| Massachusetts General Hospital | 1 |
| University of Saskatchewan | 1 |
| University of Wisconsin, Madison | 1 |
| McMaster University | 1 |
| University of Miami | 1 |
| Montefiore Medical Center | 1 |
| University of Alberta | 1 |
| St. Olavs Hospital | 1 |
| University of Virginia | 1 |
| Norwegian University of Science and Technology | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| University Hospital, Toulouse | 1 |
| Medical University of Silesia | 1 |
| Karolinska Institutet | 1 |
| Washington University School of Medicine | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 10 |
| Canada | 3 |
| Sweden | 2 |
| France | 2 |
| China | 1 |
| Bulgaria | 1 |
| Finland | 1 |
| Norway | 1 |
| Nepal | 1 |
| South Africa | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Cosmetology schools in the United States](https://specstream.ai/data/businesses/cosmetology-schools/united-states)
- [Livestock feed and supply stores in the United States](https://specstream.ai/data/businesses/livestock-feed-and-supply-stores/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Chimney sweeps in the United States](https://specstream.ai/data/businesses/chimney-sweeps/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
